Alnylam presents positive results from ILLUMINATE-B phase III study of lumasiran in pediatric patients with primary hyperoxaluria type 1 at the American Society of Nephrology Kidney Week.
Read time: 4 mins
Last updated:26th Oct 2020
Published:23th Oct 2020
Alnylam Pharmaceuticals, Inc. , announced positive results from the 6-month primary analysis of the ILLUMINATE-B Phase III pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of adults and children with primary hyperoxaluria type 1 (PH1).